News headlines about Depomed (NASDAQ:DEPO) have been trending somewhat positive on Friday, AlphaOne Sentiment reports. The research firm, a division of Accern, ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Depomed earned a news impact score of 0.19 on AlphaOne’s scale. AlphaOne also gave media stories about the specialty pharmaceutical company an impact score of 75 out of 100, meaning that recent news coverage is likely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Alpha One Sentiment’s analysis:
- Pain Management Therapeutics Market : Market and Growth Analysis (openpr.com)
- Global Neuropathic Pain Market to Reach US$ 8.3 Bn by 2024 End (mynewsdesk.com)
- Depomed Shares Down 47.0% Since SmarTrend’s Sell Call (DEPO) (mysmartrend.com)
Several research analysts recently issued reports on the company. JMP Securities reaffirmed an “outperform” rating and set a $16.00 target price (down from $30.00) on shares of Depomed in a research report on Thursday, March 30th. Janney Montgomery Scott reaffirmed a “buy” rating on shares of Depomed in a research report on Monday, February 27th. Roth Capital set a $24.00 target price on Depomed and gave the stock a “buy” rating in a research report on Saturday, February 18th. Vetr raised Depomed from a “sell” rating to a “hold” rating and set a $15.44 target price for the company in a research report on Thursday, March 2nd. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $19.00 target price on shares of Depomed in a research report on Wednesday, March 29th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $18.72.
Depomed (NASDAQ:DEPO) traded down 2.99% on Friday, hitting $11.37. The stock had a trading volume of 1,450,435 shares. The stock’s 50-day moving average is $14.12 and its 200-day moving average is $18.45. The company’s market cap is $706.07 million. Depomed has a 52-week low of $11.34 and a 52-week high of $27.02.
Depomed (NASDAQ:DEPO) last announced its earnings results on Tuesday, February 21st. The specialty pharmaceutical company reported $0.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.12. Depomed had a negative net margin of 16.93% and a negative return on equity of 7.49%. The business earned $123.90 million during the quarter, compared to the consensus estimate of $123 million. During the same quarter last year, the firm earned $0.16 earnings per share. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. Analysts expect that Depomed will post $0.97 earnings per share for the current year.
WARNING: “Depomed (DEPO) Earning Somewhat Favorable Press Coverage, Study Shows” was reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/04/21/depomed-depo-earning-somewhat-favorable-press-coverage-study-shows.html.
Depomed Company Profile
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc and related companies with MarketBeat.com's FREE daily email newsletter.